$240,000.00 in Sales Expected for Vascular Biogenics Ltd (NASDAQ:VBLT) This Quarter

Share on StockTwits

Wall Street brokerages expect Vascular Biogenics Ltd (NASDAQ:VBLT) to report $240,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Vascular Biogenics’ earnings, with the highest sales estimate coming in at $280,000.00 and the lowest estimate coming in at $200,000.00. Vascular Biogenics posted sales of $100,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 140%. The company is scheduled to issue its next earnings results before the market opens on Thursday, November 14th.

On average, analysts expect that Vascular Biogenics will report full-year sales of $810,000.00 for the current fiscal year, with estimates ranging from $700,000.00 to $920,000.00. For the next financial year, analysts anticipate that the firm will report sales of $870,000.00, with estimates ranging from $600,000.00 to $1.13 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Vascular Biogenics.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.25 million. Vascular Biogenics had a negative net margin of 3,021.20% and a negative return on equity of 35.35%.

A number of analysts recently weighed in on VBLT shares. Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Thursday, August 29th. Chardan Capital restated a “hold” rating and set a $3.00 target price on shares of Vascular Biogenics in a research note on Tuesday, August 13th. Finally, ValuEngine lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $2.38.

Shares of VBLT opened at $1.26 on Thursday. The stock has a market capitalization of $44.85 million, a PE ratio of -2.03 and a beta of -0.29. Vascular Biogenics has a 1 year low of $0.60 and a 1 year high of $1.90. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.45 and a current ratio of 6.45. The company’s 50-day simple moving average is $1.27 and its 200-day simple moving average is $1.26.

Several hedge funds have recently added to or reduced their stakes in the stock. Athena Capital Advisors LLC increased its stake in shares of Vascular Biogenics by 216.7% in the 2nd quarter. Athena Capital Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 23,950 shares during the period. Morgan Stanley increased its stake in shares of Vascular Biogenics by 6.5% in the 2nd quarter. Morgan Stanley now owns 295,012 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 17,900 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Vascular Biogenics by 66.7% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 37,500 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 15,000 shares during the period. Hedge funds and other institutional investors own 5.38% of the company’s stock.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Article: What is diluted earnings per share (Diluted EPS)?

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Asian Fintech Hits Market Cap of $1.93 Million
Asian Fintech Hits Market Cap of $1.93 Million
QunQun Reaches 24 Hour Trading Volume of $743,683.00
QunQun Reaches 24 Hour Trading Volume of $743,683.00
Asura Coin Price Reaches $0.0002 on Major Exchanges
Asura Coin Price Reaches $0.0002 on Major Exchanges
Analysts Expect Bottomline Technologies  Will Post Quarterly Sales of $108.92 Million
Analysts Expect Bottomline Technologies Will Post Quarterly Sales of $108.92 Million
$36.24 Million in Sales Expected for Cedar Realty Trust Inc  This Quarter
$36.24 Million in Sales Expected for Cedar Realty Trust Inc This Quarter
Diamond Price Tops $0.30 on Exchanges
Diamond Price Tops $0.30 on Exchanges


© 2006-2019 Ticker Report